Myelodysplastic Syndrome Clinical Trials in Chicago, Illinois

5 studies are recruiting for myelodysplastic syndrome in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   349 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

2. Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   144 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06577441 on ClinicalTrials.gov

3. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   Lurie Children's Hospital-Chicago, Chicago, Illinois

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov

4. Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

   This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Comprehensive Cancer Center, Chicago, Illinois

   Locations

   22 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06484062 on ClinicalTrials.gov

5. Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

   The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Locations

   16 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06419634 on ClinicalTrials.gov